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Abstract
Background: The level of quality of care of ambulatory services in Switzerland is almost completely unknown. By
adapting existing instruments to the Swiss national context, the present project aimed to define quality indicators
(QI) for the measurement of quality of primary care for use on health insurance claims data. These data are pre-
existing and available nationwide which provides an excellent opportunity for their use in the context of health
care quality assurance.
Methods: Pragmatic 6-step process based on informal consensus. Potential QI consisted of recommendations
extracted from internationally accepted medical practice guidelines and pre-existing QI for primary care. An
independent interdisciplinary group of experts rated potential QI based on explicit criteria related to evidence,
relevance for Swiss public health, and controllability in the Swiss primary care context. Feasibility of a preliminary
set of QI was tested using claims data of persons with basic mandatory health insurance with insurance at one of
the largest Swiss health insurers. This test built the basis for expert consensus on the final set of QI.
Results: Of 49 potential indicators, 23 were selected for feasibility testing based on claims data. The expert group
consented a final set of 24 QI covering the domains general aspects/ efficiency (7 QI), drug safety (2), geriatric care
(4), respiratory disease (2), diabetes (5) and cardiovascular disease (4).
Conclusions: The present project provides the first nationwide applicable explicit evidence-based criteria to measure
quality of care of ambulatory primary care in Switzerland. The set intends to increase transparency related to quality
and variance of care in Switzerland.
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Background
A broad spectrum of initiatives aim to increase the quality
of primary care in Switzerland [1–3]. These initiatives in-
clude a variety of different approaches such as certification
measures [4–6], in-house medical guideline development
or quality circles [7] that vary in terms of regional spread,
objectives, target population, and evidence basis. Despite
this wide range of projects, the level of quality of care of
ambulatory services in Switzerland is almost completely
unknown [8]. This is especially paradoxical, as the Swiss
health insurance act (Art. 22a Krankenversicherungsge-
setz) requires the collection of quality information in the
context of Swiss basic mandatory health insurance. Since
several years, the Swiss Federal Office of Public Health is
working on strategies to realise these requirements, which
are practically disregarded within the current collective
tariff agreements such as TARMED, the tariff system of
ambulatory medical procedures in Switzerland [9]. How-
ever, results or at least initiatives addressing this issue are
still lacking. Therefore, the topic of developing defined
and feasible approaches for national quality assurance in
ambulatory care are of great political and practical
relevance.
According to the Institute of Medicine (IOM) report, To
Err Is Human, most errors in health care result from ineffi-
cient and variable processes, changing case mix of patients,
inconsistencies in health service reimbursement systems,
differences in provider education and experience, and
numerous other factors [10]. However, quality improve-
ment is not possible without quality measurement [11].
Quality indicators (QI) are measurable items designed
to assess, compare, and improve quality of health
services [12]. So far, there are no QI for measurement of
quality of care of primary care outpatient services estab-
lished for application within the Swiss healthcare setting,
despite some small certification programs, on a volun-
tary basis.
Although there are well-known limitations, health insu-
rance claims data of mandatory basic health insurance pro-
vide a valuable opportunity for their use in the context of
health care quality assurance. These real world data are
pre-existing, nationwide available, and they link information
on individual patients with information on healthcare
providers, settings and health plans. Therefore, they allow
for both cross-sectional and longitudinal evaluations on dif-
ferent levels from the individual patient to the system level.
As Switzerland is lagging behind other European countries
with respect to quality measurement in the ambulatory
sector [13–16], the present project aims to define a set of
evidence-based QI for the measurement of quality of pri-
mary care [17, 18]. To increase applicability without the bar-
rier of huge preceding investments the QI are intended to
be used on Swiss health insurance claims data. The present
study responds to political discussions about how to
increase transparency related to quality of ambulatory care
in Switzerland by pragmatically combining pre-existing
evidence-based methods with local expertise.
Methods
Context of the study
Health insurance is mandatory for all persons residing in
Switzerland. The basic health insurance package is the
same in the entire country and includes all outpatient or
hospital medical treatments deemed appropriate, medic-
ally effective, and cost-effective. Supplementary hospital
insurance in Switzerland can be purchased, if individuals
wish further comfort of a semiprivate or private ward or
treatment in another canton for personal reasons. There
are about 60 insurance companies providing basic health
coverage in Switzerland, and they offer a range of diffe-
rent premiums and health plans from which Swiss resi-
dents are free to choose [19]. Registering with a GP is
generally not required, and residents insured in the
standard insurance plan have free choice among mostly
self-employed GPs. However, persons are free to enrol in
managed care plans (e.g. integrated care plans, telephone
triage plans, capitated and non-capitated plans) in which
they need to contact a specific primary care provider
before seeking care with other healthcare providers. In
2016, there were 0,95 generalist physicians per 1000 in-
habitants in the ambulatory sector [20]. Primary (and
specialist) care tends to be physician-centered, with
nurses and other health professionals playing a relatively
small role [21]. The present project is an initiative of the
health services research department of Helsana Group.
Helsana is one of the largest Swiss health insurances
covering about 15% of the Swiss population from all
parts of the country.
Study protocol
The process of defining suitable QI consisted of several
steps (Fig. 1). In Switzerland, there is no formal or national
process or institution responsible for summarizing and
operationalization of evidence for quality improvement
purposes. National guidelines for primary care in
Switzerland are lacking. However, the Swiss and the
German health system have many structural similarities
such as the existence of a social health insurance system,
the public/ private mix of health service providers, the
choice between various competing health insurances, and
financing of health care costs by premiums, public funds,
and co-payments. Moreover, there are no linguistic
barriers as both countries are part of the
German-speaking area. Therefore, the present project
based on recommendations from guidelines of the
German association of primary care and family medi-
cine (Deutsche Gesellschaft für Allgemeinmedizin und
Familienmedizin, DEGAM) and the German National
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Disease Management Guidelines (Nationale Versor-
gungsLeitlinien, NVL) and on QISA (QI for primary
care, developed by the AQUA Institute) indicators.
Development of guidelines or QI followed an estab-
lished clearly defined and internationally acknow-
ledged methodology [22–24].
In a first step, we extracted all recommendations for or
against specific medical interventions of all currently
existing DEGAM and NVL guidelines and all QISA. Not
all recommendations and QI extracted can be constructed
using the information that is available in health insurance
claims. Therefore, in a second step, this list of potentially
eligible items for QI was checked for operationalisability
on Swiss health insurance claims data. In a third step, a
multidisciplinary group of 9 independent experts (Swiss
Quality Indicator for Primary Care (SQIPRICA) Working
Group) from primary care, public health, and health eco-
nomics including patient and consumer representatives
rated the list of potential QI. Criteria for rating were rele-
vance for public health, clarity of definition, influence on
measured aspect of care, risk of undesired effects, and
strength of evidence. The rating process was derived from
the methodology used for development of QI in the
context of national disease management guidelines in
Germany [22]. Influenceability was defined as the po-
tential of a GP to modify care. For example, interven-
tions generally done in the hospital setting were
considered to be not influenceable. Experts were
asked to rate the potential indicators according to a 4
point Likert scale (1 = incorrect; 2 = rather incorrect;
3 = rather correct; 4 = fully correct). For the aspect
risk of undesired effects, they were asked to answer
yes or no. The aim of including the expert group was
to ensure that the resulting QI were calculable, rele-
vant, and influenceable by primary care within the
Swiss healthcare system.
As a fourth step, there was a face-to face-meeting of
the project team and the expert group. The objective of
that workshop was to discuss discrepant rating results
and principal difficulties, to converse the strengths and
limitations of claims data in this context, and to reach
consensus on a preliminary set of QI qualifying for a
first practical test. For preparation of the workshop, the
experts received a descriptive analysis of the rating
results (mean, median, range of Likert scale ratings) for
each candidate QI by criterion (i.e. relevance for public
health, clarity of definition, influence on measured
aspect of care, risk of undesired effects, and strength of
evidence). We did not apply any cut-points for exclusion
based on Likert score rating results. Therefore, the ra-
ting results of all potential indicators included in step 3
were made visible to the expert group members and
were used as a basis for discussion in the group.
The fifth step was a feasibility test. This was done using
claims data of 950′000 adult persons with basic mandatory
health insurance in the year 2013. The patient-level database
included information on socio-demographics, health insur-
ance status, prescribed drugs, health care utilization and its
associated costs as well as hospital discharge information
and the date of death. In this sample, the proportion of per-
sons presenting with the QI at interest was calculated, strati-
fied by socio-demographic (age class, sex, resident in French
or Italian speaking canton, amount of individually eligible
annual deductible, voluntary choice of a managed care
health plan) and clinical (cancer, cardiovascular disease, psy-
chological disorders as measured using pharmaceutical cost
Fig. 1 Study protocol
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groups (PCG)) characteristics [25]. Inefficient me-too medi-
cations were operationalized based on the list published by
Fricke & Klaus [26]. Potentially Inappropriate Medication
(PIM) are pharmaceuticals associated with an increased risk
for adverse drug reactions in older persons that should be
avoided whenever possible, according to expert consensus.
PIM were defined based on the Beers criteria and the PRIS-
CUS list [27, 28]. Each active agent and combinations from
these lists were attributed to one or more ATC Anatomical
Therapeutic Chemical Classification System (ATC) codes
[29]. The definition of PIM variables accounted for the fact
that certain medications were considered inappropriate only
above a certain dose or for long-term use. Analyses were
performed using the statistical package R, version 3.2.0 (R
Foundation for Statistical Computing, Vienna, Austria).
As a final (sixth) step a second workshop with the ex-
pert group was performed to discuss the results of the
feasibility test, to receive recommendations for adapta-
tion and to reach consensus about the final set of QI.
Ethical approval
The analysis complied with the Swiss Federal Law on
data protection. All data were anonymized and
de-identified prior to the performed analysis to protect
the privacy of patients, physicians, and hospitals. Ac-
cording to the national ethical and legal regulation, an
ethical approval was not needed because the data were
retrospective, pre-existing, and de-identified. Since data
was anonymized, no consent of patients was required.
Results
We extracted guideline recommendations and QI from
12 National Disease Management Guidelines, 12 QiSA
indicator sets and 8 DEGAM primary care S3 guidelines.
We excluded duplicates, services that are not part of
the basic mandatory health insurance package in
Switzerland and measures that cannot be mapped using
claims data such as details of clinical processes, decision
making, or communication that are not relevant for re-
imbursement. A list of 49 potential QI was sent to the
expert group for rating of relevance for public health,
clarity of definition, influence on measured aspect of
care, risk of undesired effects, and strength of evidence.
Overall, there were few discrepancies related to the rat-
ing across the group. All potential QI were assigned high
values for the aspect “relevance for public health” (mean
and median 3 = “rather correct”).
Table 1 lists those indicators that were – according to
expert consensus - rated inadequate for use as a QI in the
Swiss healthcare setting and were therefore excluded. Rea-
sons for exclusion were the indicator not being influenceable
by primary health care providers, being irrelevant for Swiss
primary healthcare due to medical practice, medication
market or patient population, or the indicator not being
calculable due to lack of clinical information in health insur-
ance claims data. These concerns were reflected in consis-
tently low Likert scores for “influence on measured aspect
of care” and “risk of undesired effects” for all those potential
QI listed in Table 1. The workshop resulted in a set of 23
preliminary indicators qualifying for the feasibility test cove-
ring the domains general aspects/ efficiency (7 QI), drug
safety (2), geriatric care (4), respiratory disease (3), diabetes
(4) and cardiovascular disease (3).
The results of the feasibility test were discussed in a
second face-to face meeting of the project team and the ex-
pert group. According to the experts assessment, the feasi-
bility test revealed that it was possible to operationalize all
preliminary indicators, and all indicators were sensitive to
age, gender, PCG, and to characteristics of health insurance.
However, based on discussion related to actual public
health needs, applicability and influenceability, the expert
committee decided to modify the preliminary set as follows:
1 asthma indicator was dropped because of limited control
of primary care physician. The definition and number of
indicators related to diabetes mellitus were made more
consistent with recent Swiss real-life evidence [30–32]. In
addition, the indicators relating to care for patients with
cardiovascular disease were made more specific by investi-
gating therapy with statins and ASS separately in two differ-
ent patient subgroups (i.e. patients after myocardial
infarction and patients after stroke). Based on informal con-
sensus, the experts passed a final set of 24 QI including 7
QI measuring general aspects/ efficiency, 2 QI assessing
drug safety, 4 QI related to geriatric care, and 11 QI mea-
suring the management of highly prevalent chronic diseases
(2 respiratory disease, 5 diabetes mellitus, 4 cardiovascular
disease) (Table 2).
Discussion
The present project provides the first evidence-based
nationwide measures for quality of primary ambulatory
care in Switzerland applicable on pre-existing data. The
consensus process resulted in 24 indicators that are - in
principle - ready for use in a broad variety of contexts. For
example, 4 indicators for quality care of diabetes patients
have been recently included in pay-for-performance (P4P)
contracts between networks of primary care physicians
and a Swiss health insurance [33]. On a higher level, the
proposed QI help to increase transparency related to the
level of and awareness for variance of quality of primary
care in Switzerland. In addition, they may build the basis
for quality assurance projects of health service providers.
Therefore, such indicators may also be helpful for decision
making of all stakeholders in the Swiss health system.
Recently, Ebert et al. published the Swiss Primary
Care Active Monitoring (SPAM) instrument consisting
of 56 indicators related to the organization of primary
care in Switzerland. SPAM tool aims to support a better
Blozik et al. BMC Health Services Research  (2018) 18:743 Page 4 of 11
understanding of the Swiss PC system’s performance
and effectiveness on a meta level [34]. It addresses col-
laboration and coordination of stakeholders, access,
and supply of services and care providers. But does not
focus on quality in various clinical situations as our in-
dicators do. Thus, most SPAM aspects are not included
in reimbursement information and can thus not be
measured based on health insurance claims data.
Table 1 Results of the first workshop: rated inappropriate for use as a QI in the Swiss healthcare setting
Category Potential indicator Reason
General aspects, efficiency Proportion of patients enrolled in health plans per
region
Not related to quality of primary care
General aspects, efficiency Proportion of hospitalisations for interventions that
can be adequately done in the ambulatory setting
Measures quality of hospital care/ hospital processes
General aspects, efficiency Number of hospitalisations per 1000 persons Rather a measure of hospital processes, and density
parameters than of primary care
General aspects, efficiency Proportion of patients receiving medication therapy No clear indicator of quality. Not specific to primary
care.
General aspects, efficiency Share of prescriptions of new me-too medications
of the total market
A current classification of me-too medications is not
available for Switzerland
Respiratory disease Proportion of patients with asthma or COPD receiving
combinations of reproterol & cromoglicinic acid
reproterol and cromoglicinic acid are not on the Swiss
market/ use is very unusual
Respiratory disease Proportion of patients with asthma or COPD receiving,
die N-acetylcystein, ambroxol or myrtol for elimination
of secret
Medications are not on the Swiss market/ use is very
unusual
Respiratory disease Proportion of patients with COPD receiving
pneumococcal vaccination
Asthma and COPD cannot be differentiated in the claims
dataset because ambulatory diagnoses are lacking
Respiratory disease Proportion of pregnant women with incident therapy
with leukotriene receptor antagonists
Relatively small number of cases, therefore not suitable
for large scale measurement
Respiratory disease Proportion of pregnant women with incident specific i
mmunotherapy
Relatively small number of cases, therefore not suitable
for large scale measurement
Respiratory disease Proportion of children/ teenagers with asthma receiving
oral beta-2-sympathomimetics in acute situations
Clinial information is missing
Respiratory disease Proportion of patients with asthma receiving inhalative
medication
Identification of patients is based on medication.
Therefore, no meaningful interpretation of results possible.
Respiratory disease Proportion of patients with asthma with long term
inhalative corticosteroids
Asthma and COPD cannot be distinguished using claims
data.
Identification of patients is based on medication.
Therefore, no meaningful interpretation of results possible.
Cardiovascular disease Proportion of patients with heart failure receiving
laboratory control of electrolytes and renal function
semi-yearly
Population cannot be determined because ambulatory
diagnoses are lacking in Swiss health insurance claims
Cardiovascular disease Proportion of patients after coronary stent implant
receiving triple therapy
(ASS + Clopidogrel + Anticoagulation)
Measures quality of care of cardiologists/ interventional
cardiologists (as opposed to primary care)
Cardiovascular disease Proportion of patients after aortocoronary Bypass /
acute coronary syndrome and Anticoagulation only
Measures quality of care of cardiologists/ interventional
cardiologists (as opposed to primary care)
Measures quality of hospital care
Cardiovascular disease Proportion of patients after coronary bypass receiving
multidisciplinary rehabilitation
No coherent way of accounting of rehabilitation services
in Switzerland, no information about multidisciplinarity
Cardiovascular disease Proportion of ambulatory patients with laboratory test
for BNP und NT-proBNP
Recommendation is not clear enough.
Depression Proportion of patients resistant to depression treatment
receiving augmentation of antidepressants with
carbamazepine, lamotrigine, pindolol, valproate,
dopamine agonists, psychostimulants, thyroid
hormone or other hormones
Clinical information is missing
Diabetes mellitus Proportion of patients with pain in diabetic neuropathy
treated with traditional nonsteroidal antiphlogistics
Clinical information is missing
Diabetes mellitus Proportion of patients with pain in diabetic neuropathy
treated with selective Cox-2 inhibitors
Clinical information is missing
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Therefore, SPAM complements the QI proposed by our
group. Measuring quality both on the individual patient
level and on a health system level might multiply
insight in potential ways to improve quality of ambula-
tory primary care in Switzerland. The QI identified in
the present study provide the opportunity to compare
physician networks or even individual health service
providers and therefore expand the operational conclu-
sions that may be drawn from quality measurement.
Several limitations need to be considered. Firstly, we re-
cruited a quasi-representative sample of experts for adapting
international evidence to the Swiss healthcare setting.
Therefore, the participants were not official representatives
of stakeholder institutions but were selected based on their
expertise related to primary care and/ or the Swiss health
system. Secondly, the project was done from the perspective
of Swiss mandatory basic health insurance. Therefore, ser-
vices usually performed outside of the basic health insurance
package were systematically not addressed in this project
(e.g. services of supplementary insurance, over the counter
medication, health-related life style, health promotion and
prevention). However, the Swiss Swiss mandatory basic
health insurance covers a very broad spectrum of all services
needed for management of illness, accidents, and mother-
hood deemed to be effective, appropriate. and cost-efficient
[35]. Thirdly, as our aim was to define QI for application on
health insurance claims, we had to systematically exclude all
aspects of quality that were not relevant for billing in the
system of basic health insurance in Switzerland. Therefore,
quality as reflected in satisfaction, communication, informa-
tion, decision-making, or clinical results that impact the
provision of health services at interest need to be
addressed elsewhere. Fourthly, evidence-based QI can
only be as good as the underlying evidence. There-
fore, several aspects might be systematically under-or
overrepresented depending on the presence or ab-
sence of evidence in certain clinical areas. Finally,
data for feasibility testing came from a single health
insurance, and results might differ when including
data from other health insurances. However, the Hel-
sana Group covers about 15% of the Swiss population,
and the representative nature of the data has repea-
tedly been shown before [36, 37].
The main strength of the project is the pragmatic
methodology in response to current public debates on
quality assurance in ambulatory care. The present
study combined pre-existing evidence-appraisal from
devoted institutions in Germany, internationally ac-
cepted methods for QI development, local expertise,
and the pre-existing nature of health insurance claims
data. Moreover, both the patient and the consumer
perspective were represented in the expert group as
considered the gold standard for the development of
QI [38, 39].
The present study has implications for future research.
First, use of the proposed indicators needs to be evaluated.
Specifically, future studies should assess if and how beha-
viour of physicians, frequency of unwarranted events such
as hospitalisations, or costs change after introduction of
P4P contracts. This is especially relevant since the evi-
dence for P4P is not yet fully clarified, and international
experiences are discussed controversially [40, 41].
Secondly, variance of quality across regions, settings,
health insurance plans and patient groups need to be
explored. Thirdly, an evidence-based instrument needs
continuous update, evaluation, and continual adaptation
[42]. For example, a current research project aims to de-
velop QI for multimorbidity [43], and such indicators
might be suitable for adaptation to the Swiss context
and for future integration in the present set of QI.
In practice, QI constructed upon health insurance
claims may provide the impetus to increase efforts for
more quality in Swiss primary healthcare, to differentiate
incentives for health care providers, and to increase
quality competition across health care providers, health
plans, and health insurances. The present QI may build
the basis for the implementation of models that fit the
Swiss needs.
Conclusions
Based on pre-existing foreign clinical practice guidelines and
QI and on an informal expert consensus process we identi-
fied a broad set of QI for the measurement of quality of pri-
mary care in Switzerland that can be applied on nation-wide
available health insurance claims data. Implementation of
these indicators needs to be evaluated so that this set of QI
can be continuously ameliorated and expanded. Local evi-
dence related both to the level of quality of primary care
and to the positive and negative effects of implementation
of QI is urgently needed.
Abbreviations
ASS: Acetylsalicylic acid; ATC: Anatomical therapeutic chemical classification
system; COPD: Chronic obstructive pulmonary disease; DDD: Defined daily
dose; NSAID: Nonsteroidal anti-inflammatory drug; PCG: Pharmacy cost
group; PIM: Potentially inappropriate medication; QI: Quality indicator
Acknowledgements
The methods of this project and preliminary results were presented at the
symposia health services research of the Swiss Academy of Medical Sciences
(SAMW), Bern 2015 and 2017, the annual meeting of the Swiss forum for
integrated care (fmc), Bern 2016, the annual conference of the German
association of primary care and family medicine (DEGAM), Frankfurt 2016,
annual meeting of the European Association of Health Economics (EuHEA),
Hamburg, 2016, and at the expert meeting of the EQUAM Foundation, Bern,
2017.
The Swiss Quality Indicator for Primary Care (SQIPRICA) Working Group
members were:
PD Dr. med. Sima Djalali, Assistant physician, Spital Zollikerberg and Research
Associate, Institute of Primary Care, University of Zürich, Zürich, Switzerland.
Dr. med. Felix Huber, Medical director, MediX group practices Zürich, Zürich,
Switzerland.
Dr. med. René Kühne, Department of Health Policy, Helsana Health
Insurances, Zürich, Switzerland,
Blozik et al. BMC Health Services Research  (2018) 18:743 Page 9 of 11
Dr. med. Jan von Overbeck, Cantonal physician, Canton of Bern, Bern,
Switzerland,
Prof. Dr. Dr. med. Thomas Rosemann, Director, Institute of Primary Care,
University of Zurich, Switzerland,
Felix Schneuwly, Head of Public Affairs Swiss online comparative service
Comparis, Zürich, Switzerland,
Prof. Dr. Martin Scherer, Director Department of General Practice/Primary
Care, Hamburg University Medical School, Hamburg-Eppendorf, Hamburg,
Germany.
Prof. Dr. med. Oliver Senn, Institute of Primary Care, University of Zurich,
Zürich, Switzerland,
med. Pract. Daniel Tapernoux, medical advisor, Swiss Patient Organisation
(SPO), Zürich, Switzerland.
Funding
Own resources of Helsana Health Insurances AG. The funder provided
support in the form of salaries but did not have any additional role in the
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Availability of data and materials
The datasets analysed during the current study are not publicly available
because they are part of the confidential Helsana health insurance claims
database. Additional information not included in the paper is available from
the corresponding author on reasonable request.
Authors’ contributions
All authors were involved in the study design. EB, OR, and MS conceived and
designed the study. RR analysed the data. EB drafted the manuscript. OR, RR,
MS, and the members of the Quality Indicator for Primary Care Working
Group revised the manuscript. All authors participated in the interpretation
of data, critically reviewed for important intellectual contents and gave the
final approval of the version to be published.
Ethics approval and consent to participate
The analysis complied with the Swiss Federal Law on data protection.
According to the national ethical and legal regulation, an ethical approval
was not needed because the data were retrospective, pre-existing, and de-
identified. Since data was anonymized, no consent of patients was required.
Therefore, ethical approval and consent were waived.
Consent for publication
Not applicable.
Competing interests
EB, RR, and OR were affiliated with the Helsana Health Insurance Company at
the time when the study was conducted. MS heads the guideline
commission of the DEGAM (Ständige Leilinienkommission, SLK). EB is
member of the SLK.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Health Sciences, Helsana Group, P.O. Box, Zürich,
Switzerland. 2Department of General Practice/Primary Care, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3Division of
General Practice, University Medical Centre Freiburg, Freiburg, Germany.
Received: 21 February 2018 Accepted: 16 August 2018
References
1. Senn N, Ebert ST, Cohidon C. Obsan Bulletin 11/2016: Die Hausarztmedizin
in der Schweiz – Perspektiven. Analyse basierend auf den Indikatoren des
Programms SPAM (Swiss Primary Care Active Monitoring). Swiss Health
Observatory: Neuchâtel; 2016.
2. Schweizer Forum für Intergrierte Versorgung fmc: Neue
Versorgungsmodelle für die medizinische Grundversorgung. Bericht der
Arbeitsgruppe “Neue Versorgungsmodelle für die medizinische
Grundversorgung” von GDK und BAG. 2012. https://www.fmh.ch/files/
pdf13/versorgungsmodelle_d.pdf. Accessed 10 Feb 2018.
3. Chmiel C, Bhend H, Senn O, Zoller M, Rosemann T. The FIRE project: a
milestone for research in primary care in Switzerland. Swiss Med Wkly. 2011;
140:w13142.
4. EQUAM Stiftung: Unser Angebot. 2018. https://www.equam.ch/de/.
Accessed 10 Feb 2018.
5. Mehrfacharzt: Die Zertifizierung als “MehrFachArzt” oder “MehrFachÄrztin”.
2018. http://www.mehrfacharzt.ch/fuer-hausaerzte/zertifizierung/. Accessed
10 Feb 2018.
6. QBM-Stiftung: QBM – von Ärzten für Ärzte. 2018. https://www.qbm-stiftung.
ch/qbm.html. Accessed 10 Feb 2018.
7. Berchtold P, Schmitz C, Maier J. Obsan Report 51: Guidelines in Schweizer
Ärztenetzen. Entwicklung und Bedeutung. Swiss Health Observatory:
Neuchâtel; 2012.
8. Meyer K. Gesundheit in der Schweiz – Nationaler Gesundheitsbericht 2008.
Swiss Health Observatory: Neuchâtel; 2010.
9. Swiss Federal Office of Public Health: Quality Assurance. 2018. https://www.
bag.admin.ch/bag/en/home/themen/versicherungen/krankenversicherung/
krankenversicherung-qualitaetssicherung.html. Accessed 10 Feb 2018.
10. Institute of Medicine. To err is human: building a safer health system.
Washington, DC: National Academy Press; 1999.
11. Lester H, Roland M. Performance measurement in primary care. In: Smith P,
Mossialos E, Papanicolas I, Leatherman S, editors. Performance Measurement
for Health System Improvement. Cambridge: Cambridge University Press; 2009.
12. Campbell SM, Kontopantelis E, Hannon K, Burke M, Barber A, Lester HE.
Framework and indicator testing protocol for developing and piloting
quality indicators for the UK quality and outcomes framework. BMC Fam
Pract. 2011;12:85.
13. Swiss Federal Office of Public Health: Comparisons and Analyses of Health
Systems. 2018. https://www.bag.admin.ch/bag/en/home/themen/
internationale-beziehungen/internationalegesundheitsthemen/
comparaisons-analyses-systemes-sante.html. Accessed 19 April 2018.
14. Swiss Federal Office of Public Health: Ein Netzwerk für mehr Qualität in der
Gesundheitsversorgung. 2018. https://www.bag.admin.ch/bag/de/home/
themen/versicherungen/krankenversicherung/krankenversicherung-
revisionsprojekte/netzwerk-qualitaet-gesundheitsversorgung.html. Accessed
19 April 2018.
15. Limb M. OECD finds some countries are too restrictive about sharing
personal data. BMJ. 2013;346:f2116. https://doi.org/10.1136/bmj.f2116.
16. Swiss Academy of Medical Sciences. Stärkung der Versorgungsforschung in
der Schweiz. Swiss Academies Reports 2014; 9(1). https://www.samw.ch/de/
Publikationen/Positionspapiere.html. Accessed 19 April 2018.
17. Cohidon C, Cornuz J, Senn N. Primary care in Switzerland: evolution of
physicians’ profile and activities in twenty years (1993–2012). BMC Fam
Pract. 2015;16:107.
18. Tandjung R, Hanhart A, Bärtschi F, Keller R, Steinhauer A, Rosemann T, Senn
O. Referral rates in Swiss primary care with a special emphasis on reasons
for encounter. Swiss Med Wkly. 2015;145:w14244.
19. Swiss Federal Office of Public Health: Statistik der obligatorischen
Krankenversicherung. 2018. https://www.bag.admin.ch/bag/de/home/
service/zahlen-fakten/statistiken-zur-krankenversicherung/statistik-der-
obligatorischen-krankenversicherung.html. Accessed 10 Feb 2018.
20. Hostettler S, Kraft E. FMH-Ärztestatistik 2016 36 175 berufstätige Ärztinnen
und Ärzte. Schweiz Ärzteztg. 2017;98(13):394–400.
21. The Commonwealth Fund: The Swiss Health Care System. 2016. https://
international.commonwealthfund.org/countries/switzerland/ Accessed 01
Aug 2018.
22. Programm für Nationale VersorgungsLeitlinien von BÄK, KBV und AWMF:
Qualitätsindikatoren– Manual für Autoren. 2009. http://www.aezq.de/mdb/
edocs/pdf/schriftenreihe/schriftenreihe36.pdf. Accessed 10 Feb 2018.
23. AQUA Institut: Allgemeine Methoden. 2015. https://www.aquainstitut.de/
fileadmin/aqua_de/Projekte/248_Methodenpapier/Methodenpapier_4.0.pdf.
Accessed 10 Feb 2018.
24. German College of General Practitioners and Family Physicians: S3-Leitlinien
der DEGAM - der Zehnstufenplan. 2009. http://www.degam.de/id-10-stufen-
plan.html. Accessed 10 Feb 2018.
25. Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic
conditions using pharmacy data in Switzerland: an updated mapping
approach to the classification of medications. BMC Public Health. 2013;13:
1030.
Blozik et al. BMC Health Services Research  (2018) 18:743 Page 10 of 11
26. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2016. Berlin: Springer;
2016.
27. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in
the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543–51.
28. American Geriatrics Society. Beers Criteria Update Expert Panel. American
Geriatrics Society updated Beers Criteria for potentially inappropriate
medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.
29. World Health Organization: ATC/DDD Index. 2018. http://www.whocc.no/
atc_ddd_index/. Accessed 10 Feb 2018.
30. Huber CA, Brändle M, Rapold R, Reich O, Rosemann T. A set of four simple
performance measures reflecting adherence to guidelines predicts
hospitalization: a claims-based cohort study of patients with diabetes.
Patient Prefer Adherence. 2016;10:223–31.
31. Huber CA, Rapold R, Brüngger B, Reich O, Rosemann T. One-year adherence
to oral antihyperglycemic medication and risk prediction of patient
outcomes for adults with diabetes mellitus: An observational study.
Medicine (Baltimore). 2016;95(26):e3994.
32. Huber CA, Reich O, Früh M, Rosemann T. Effects of Integrated Care on
Disease-Related Hospitalisation and Healthcare Costs in Patients with
Diabetes, Cardiovascular Diseases and Respiratory Illnesses: A Propensity-
Matched Cohort Study in Switzerland. Int J Integr Care. 2016;16(1):11.
33. Schweizer Forum für Intergrierte Versorgung fmc: Presentation of Schmutz
DH at the Swiss national Symposium of Integrated Care2016, Bern,
Switzerland. Performance-basierte Vergütung: Auch im Gesundheitswesen?
2016. https://fmc.ch/_Resources/Persistent/
44cf7867c819aec35e6beac171ce7640ccf60b68/2016_Keynote_4_Daniel_H_
Schmutz.pdf. Accessed 10 Feb 2018.
34. Ebert ST, Pittet V, Cornuz J, Senn N. Development of a monitoring
instrument to assess the performance of the Swiss primary care system.
BMC Health Serv Res. 17(1):789.
35. Herzlinger RE, Parsa-Parsi R. Consumer-driven health care: lessons from
Switzerland. JAMA. 2004;292(10):1213–20. https://doi.org/10.1001/jama.292.
10.1213, 292/10/1213.
36. Helsana Group: Helsana Drug Report 2017. 2017. https://www.helsana.ch/
en/helsanagroup/about-our-company/health-sciences/drug-report. Accessed
10 Feb 2018.
37. Helsana Group: Helsana Report Ausgabenentwicklung in der
Gesundheitsversorgung. 2016. https://www.helsana.ch/de/helsana-gruppe/
unternehmen/gesundheitswissenschaften/ausgabenreport. Accessed 10 Feb
2018.
38. Pohontsch NJ, Herzberg H, Joos S, Welti F, Scherer M, Blozik E. The
professional perspective on patient involvement in the development of
quality indicators: a qualitative analysis using the example of chronic heart
failure in the German health care setting. Patient Prefer Adherence. 2015;9:
151–9.
39. Kötter T, Schaefer FA, Scherer M, Blozik E. Involving patients in quality
indicator development - a systematic review. Patient Prefer Adherence.
2013;7:259–68.
40. Mendelson A, Kondo K, Damberg C, Low A, Motúapuaka M, Freeman M,
O'Neil M, Relevo R, Kansagara D. The Effects of Pay-for-Performance
Programs on Health, Health Care Use, and Processes of Care: A Systematic
Review. Ann Intern Med. 2017;166(5):341–53.
41. Ryan AM, Krinsky S, Kontopantelis E, Doran T. Long-term evidence for the
effect of payfor-performance in primary care on mortality in the UK: a
population study. Lancet. 2016;388(10041):268–74.
42. Kötter T, Blozik E, Scherer M. Methods for the guideline-based development
of quality indicators--a systematic review. Implement Sci. 2012;7:21.
43. Blozik E, Lühmann D, Scherer M. Entwicklung und Validierung von
Qualitätsindikatoren für Multimorbidität (Multiqual). In: Amelung VE, Eble S,
Hildebrandt H, Knieps F, Lägel R, Ozegowski S, Schlenker R-U, Sjuts R,
editors. Innovationsfonds, Impulse für das deutsche Gesundheitswesen.
Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft; 2017.
Blozik et al. BMC Health Services Research  (2018) 18:743 Page 11 of 11
